The role of somatostatin and its analogues in reducing complications after pancreatic resection is controversial.
Dr Connor and colleagues conducted a meta-analysis of the evidence of benefit.
The researchers undertook a literature search using Medline and ISI Proceedings.
The research team identified 22 studies, and of these, 10 met the inclusion criteria for data extraction.
|Somatostatin reduced pancreas-specific complications|
|British Journal of Surgery|
Estimates of effectiveness were performed using fixed- and random-effects models.
The team calculated the effect as an odds ratio with 95% confidence intervals using the Mantel-Haenszel method.
The level of significance was set at a p value greater than 0.05, and outcomes for 1918 patients were compared.
The researchers found that somatostatin and its analogues did not reduce the mortality rate after pancreatic surgery.
However, the team noted that somatostatin did reduce both the total morbidity and pancreas-specific complications.
The researchers observed that somatostatin and its analogues reduced the rate of biochemical fistula but not the incidence of clinical anastomotic disruption.
Dr Connor's team concluded, “Somatostatin and its analogues reduce the incidence of complications after surgery.”